© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Racial Disparities Persist in Respiratory Disease Research, Diagnostics: Expert Panel Discussion at 2024 ATS
May 28th 2024
Pulmonology experts agreed that adopting race-neutral diagnostic and research practices could help mitigate a range of inequities faced by minority populations.
Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings
May 20th 2024
ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD
May 8th 2024
The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
April 22nd 2024
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
April 20th 2024
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
April 19th 2024
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data
April 9th 2024
ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.
The Inclisiran Impact on PCSK9: A Primary Care Primer
April 8th 2024
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
April 8th 2024
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
April 6th 2024
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.